Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy

, a TROP2 ADC, demonstrated synergistic antitumor activity in triple-negative breast cancer MDA-MB-231 xenograft models.